99199-61-8

Basic information

• Product Name: 6-Fluoro-3,4-Dihydro-2H-1-Benzopyran-2-CarboxylicAcid
• Synonyms: rac-6-Fluoro-3,4-dihydro-2H-1-benzopyran-2-carboxylic Acid Ethyl Ester;Ethyl 6-Fluoro-3,4-dihydro-2H-1-benzopyran-2-carboxylate;ethyl 6-fluorochroman-2-carboxylate
• CAS NO: 99199-61-8
• Molecular Formula: C12H13FO3
• Molecular Weight: 224.23
• Product Categories: Intermediates & Fine Chemicals;Pharmaceuticals
• Mol File: 99199-61-8.mol

Chemical Properties

• Appearance: /
• Storage Temp.: Refrigerator
• Solubility: DMSO, Ethyl Acetate
• CAS DataBase Reference: 6-Fluoro-3,4-Dihydro-2H-1-Benzopyran-2-CarboxylicAcid(CAS DataBase Reference)
• NIST Chemistry Reference: 6-Fluoro-3,4-Dihydro-2H-1-Benzopyran-2-CarboxylicAcid(99199-61-8)
• EPA Substance Registry System: 6-Fluoro-3,4-Dihydro-2H-1-Benzopyran-2-CarboxylicAcid(99199-61-8)

Safety Data

• Hazardous Substances Data: 99199-61-8(Hazardous Substances Data)

Usage

Chemical Properties

Colourless Oil

Upstream product

• 99199-60-7 6-fluoro-3,4-dihydro-2H-1-benzopyran-2-carboxylic acid 

Downstream Products

• 1030385-17-1 (SRRR)-d-N-benzilnebivolol 
• 1199945-26-0 2-{benzyl-[2-(6-fluoro-chroman-2-yl)-2-hydroxy-ethyl]-amino}-1-(6-fluoro-chroman-2-yl)-ethanol 

Relevant articles and documents

PROCESS FOR THE PREPARATION OF NEBIVOLOL

The present invention relates to a novel process for the synthesis of the Nebivolol product depicted in Scheme 1, comprised of a reduced number of high-yield steps, and characterized by the enzymatic resolution of the chroman ester precursor.

Metabotropic glutamate receptor antagonists

The present invention concerns compounds of formula. In a preferable embodiment, X represents O; R1 represents C1-6alkyl; cycloC3-12alkyl or (cycloC3-12alkyl)C1-6alkyl, wherein one or more hydrogen atoms in a C1-6alkyl-moiety or in a cycloC3-12alkyl-moiety optionally may be replaced by C1-6alkyloxy, aryl, halo or thienyl; R2 represents hydrogen; halo; C1-6alkyl or amino; R3 and R4 each independently represent hydrogen or C1-6alkyl; or R2 and R3 may be taken together to form —R2-R3-, which represents a bivalent radical of formula -Z4-CH2-CH2-CH2- or -Z4-CH2-CH2- with Z4 being O or NR11 wherein R11 is C1-6alkyl; and wherein each bivalent radical is optionally substituted with C1-6alkyl; or R3 and R4 may be taken together to form a bivalent radical of formula —CH2-CH2-CH2-CH2-; R5 represents hydrogen; Y represents O; and aryl represents phenyl optionally substituted with halo. The invention also relates to the use of a compound according to the invention as a medicament and in the manufacture of a medicament for treating or preventing glutamate-induced diseases of the central nervous system, as well as formulations comprising such a compound and processes for preparing such a compound.